Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04383834
Other study ID # 2017-1538
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 1, 2019
Est. completion date May 1, 2023

Study information

Verified date May 2020
Source Studio Ban Mancini Fabbri
Contact Giacomo Fabbri, Dentist
Phone 0039541963434
Email info@bmf.dental
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Soft tissue thickness, using IOS, between implant insertion (baseline) and 3-year follow-up has no changes


Recruitment information / eligibility

Status Recruiting
Enrollment 58
Est. completion date May 1, 2023
Est. primary completion date April 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

.The subject inclusion criteria are listed below. The subject is at least 18 years of age (or age of consent) and has passed cessation of growth.

Obtained informed consent from the subject. The patient is willing and able to comply with all study related procedures (such as exercising oral hygiene and attending all follow-up procedures).

The subject shall be healthy and compliant with good oral hygiene. Full-mouth bleeding score (FMBS) lower than 25 %[10]. Full-mouth plaque score (FMPI) lower than 20% [11]. Suitable for implant treatment in the posterior, pre-molar area in the mandible or maxilla.

The subject shall have a favorable and stable occlusal relationship. In need of one single tooth replacement Healed sites in need for implant placement (i.e. minimum of 6 weeks post extraction).

The implant sites are free from infection and extraction remnants. The subject is suitable for a 1-stage surgical procedure. Sufficient amount of buccal and lingual keratinized mucosa. The healed sites eligible will have natural teeth as neighboring structures. The subject is in such a physical and mental condition that a 3-year follow up period can be carried out without foreseeable problems.

The subject has a sufficient amount of bone for placing NobelActive TiUltra with a length of at least 7 mm.

The following subject inclusion criteria apply at time of surgery:

Primary implant stability as assessed by manual hand testing.

Exclusion Criteria:

- The subject is not able to give her/his informed consent of participating. Health conditions, which do not permit the surgical (including anesthesia) or restorative procedure.

Reason to believe that the treatment might have a negative effect on the subject's overall situation (psychiatric problems), as noted in subject records or in subject history.

Any disorders in the planned implant area such as previous tumors, chronic bone disease or previous irradiation in the head/neck area.

Infections in the planned implantation site or adjacent tissue. Acute, untreated periodontitis in the planned implantation site or adjacent tissue.

Any ongoing application of interfering medication (steroid therapy, bisphosphonate, etc.).

Uncontrolled diabetes, i.e. a subject with diagnosed diabetes that has a history of neglecting doctor's recommendations regarding treatment, food and alcohol intake or A1c level above 8%.

Alcohol or drug abuse as noted in subject records or in subject history. Smoking less 10 cigarettes/day. Fresh extraction sites (up to 6 weeks). Severe bruxism or other destructive habits. Pregnant or lactating women at the time of implant insertion. Previous bone augmentation (lateral and/or vertical). Soft tissue augmentation less than 2 months before implant placement. Subject has allergic or adverse reactions to the restorative material

Study Design


Related Conditions & MeSH terms

  • to Study Soft Tissue Health and Stability

Intervention

Device:
NobelActive® TiUltra™ implants and On1™ Base/Xeal™ along with On1 components
The NobelActive® TiUltra™ implant is an ultra-hydrophilic multi-zone anodized implant surface. NobelActive® TiUltra™ features a gradual change in topography, from a minimally rough non-porous nanostructured implant collar to a moderately rough porous apex: more than roughness. NobelActive® TiUltra™ collar features surface chemistry and topography that promote early osseointegration and are designed to support bone stability. In addition, the Protective Layer preserves the pristine surface chemistry and hydrophilicity. The second new product is the Base/Xeal™ new surface, which is covered by a titanium oxide layer, created by electrochemical anodization of a titanium machined component, resulting in a yellow hue nano-structured surface.

Locations

Country Name City State
Italy Studio Ban Mancini Fabbri Cattolica Rimini

Sponsors (1)

Lead Sponsor Collaborator
Giacomo Fabbri

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary A 3-years Investigator initiated study to evaluate the soft tissue health and stability in the mandible and/or maxilla using the NobelActive® TiUltra™ and On1™ Base/Xeal™ Soft tissue thickness, using IOS, between implant insertion (baseline) and 3-year follow-up has no changes 47 months (8 months enrolment + 36 months follow up + 3 months study closure)